Metformin: Can an Old Drug Blunt the Accelerated Clock of HIV

#1

People living with HIV (PLWH) face a unique biological paradox: even when the virus is successfully suppressed by modern antiretroviral therapy (ART), their bodies often exhibit signs of “accentuated aging”. This manifests as a higher incidence of age-related comorbidities and advanced biological age compared to their HIV-negative peers. The METFORAGING trial, conducted at La Paz University Hospital in Madrid, Spain, sought to determine if the common antidiabetic drug metformin could serve as a geroprotective intervention to slow this accelerated clock.

This double-blind, randomized, placebo-controlled pilot trial assigned 40 non-diabetic PLWH (aged 50+) to receive 850 mg of metformin twice daily or a placebo for 96 weeks. The investigators utilized 11 distinct epigenetic biomarkers, including “clocks” like PhenoAge and GrimAge, which translate DNA methylation patterns into an estimate of biological age.

The headline result is statistically neutral: the primary endpoint—a change in PhenoAge—did not show a significant difference between the metformin and placebo groups after nearly two years. However, the data reveals a compelling trend. Across all nine epigenetic clocks and both telomere-length estimators, the point estimates consistently favored the metformin group. For instance, metformin users saw a reduction in PhenoAge acceleration of approximately 1.02 years relative to placebo, though the wide confidence intervals prevent this from being definitive.

Crucially, the study established that long-term metformin use is remarkably safe in this specific population. Despite the complexity of HIV management and potential drug interactions, participants maintained high adherence, validated by significant increases in serum GDF15, a known biomarker of metformin exposure. While this pilot was not powered to deliver a “slam dunk” on efficacy, it provides the requisite safety data and signal-of-intent to justify much larger, multi-center trials. In the search for affordable, scalable longevity interventions, metformin remains a primary candidate for those facing high-stress biological environments.

Actionable Insights

  • Safety Profile: This trial confirms that 1,700 mg of metformin daily is safe for non-diabetic, virologically suppressed PLWH over 96 weeks, with no serious adverse events attributed to the drug.

  • Gastrointestinal Management: Minor side effects (primarily diarrhea) are common but generally self-limited; starting with a low dose (850 mg once daily) and escalating can improve tolerance.

  • Adherence Monitoring: Serum GDF15 serves as a reliable objective marker to verify long-term adherence to metformin regimens.

  • Precision and Cell Types: The modest effect sizes in whole-blood analysis suggest that future biohacking or clinical efforts might focus on specific immune cells (like monocytes) where metformin signals appear stronger.

  • Long-Term Perspective: Longevity interventions may require durations exceeding two years to show statistically significant shifts in whole-organism biological age clocks.

Source:

1 Like